Raphaël TOMASI has been developing a unique droplet microfluidic technology to perform multiplexed 3D cell culturing on chip since 2013. He co-invented this technology during his Ph.D. in microfluidics, between 2013 and 2016, in Charles BAROUD’s laboratory at Ecole Polytechnique (Paris, France). Then, he continued developing the technology in the lab, as well as the associated business opportunity, at Institut Pasteur (Paris, France). In mid-2020, he cofounded Okomera to commercialize this technology for precision cancer medicine. Based in Paris, Okomera is launching its first product to automate drug testing on cancer cells from patient biopsies for precision cancer medicine. Raphaël TOMASI leads the technological development of Okomera as CTO.
Combinatorial Drug Screening on 3D Ewing Sarcoma Spheroids Using Droplet-based Microfluidics
Tuesday, 25 October 2022 at 11:00
Add to Calendar ▼2022-10-25 11:00:002022-10-25 12:00:00Europe/LondonCombinatorial Drug Screening on 3D Ewing Sarcoma Spheroids Using Droplet-based MicrofluidicsBioengineering for Building Microphysiological Systems 2022 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
At Okomera, we develop a unique technology for miniaturized, automated
and functional cell assays in precision cancer medicine. Our droplet
microfluidic workflow enables to encapsulate patient cancer cells from a
biopsy, and quickly form a single 3D microtumor per droplet. This
versatile microfluidic toolbox enables sequential 3D co-culture,
hydrogel encapsulation, fluorescent assays or multiplexing to up to 100
conditions per chip. Okomera provides a laboratory instrument,
microfluidic consumables and an Artificial Intelligence-powered analysis
software to extract quantitative features from microscopy images of the
chip and assess drug efficacy ex vivo.
Here, we applied concomitant and sequential drug combination of two
chemotherapies, etoposide and cisplatin to the Ewing sarcoma cell line
A673. Microtumors were formed in 500 nL droplets and then fused with
secondary droplets containing fluorescent-barcoded drugs at different
concentrations. Differences in microtumor growth and viability were
analyzed on around 300 microtumors per experiment. This enabled accurate
estimation of IC50 values for each drug, in agreement with measurements
obtained in standard non adherent multiwell plates. Using this
straightforward method, synergistic drug combination was found when both
drugs were tested simultaneously or sequentially. Interestingly,
sequential combination treatment with etoposide applied 24 h before
cisplatin resulted in an amplified synergistic effect.
Add to Calendar ▼2022-10-24 00:00:002022-10-25 00:00:00Europe/LondonBioengineering for Building Microphysiological Systems 2022Bioengineering for Building Microphysiological Systems 2022 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2022-10-25 11:00:002022-10-25 12:00:00Europe/LondonCombinatorial Drug Screening on 3D Ewing Sarcoma Spheroids Using Droplet-based MicrofluidicsBioengineering for Building Microphysiological Systems 2022 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
